96 results about "Inhalation preparations" patented technology

The invention relates to a method for refining injection-grade ambroxol hydrochloride. The method is characterized by comprising the steps of adding oral-taking-grade ambroxol hydrochloride with the proportion smaller than or equal to 20:1 into ethanol water solution with the volume ratio of 5-20%; performing heating to completely dissolve the oral-taking-grade ambroxol hydrochloride; stopping heating and performing cooling to seed out ambroxol hydrochloride; and filtering solvent to obtain crystals and drying the crystals to obtain the injection-grade ambroxol hydrochloride. The invention further relates to ambroxol hydrochloride solution for inhalation prepared by utilizing the prepared injection-grade ambroxol hydrochloride as the raw material. The atomization inhalation solution comprises the ambroxol hydrochloride, a stabilizer, a pH conditioning agent and an osmotic pressure conditioning agent. By means of the scientific preparation adopting the carrier, fewest degradation products of the atomization inhalation preparation can be produced under the high temperature of 121 DEG C for 15 minutes, the atomization inhalation preparation is stable, and the service life of the atomization inhalation preparation is prolonged to 5 years.

An inhalable formulation containing SAE-CD and corticosteroid is provided. The formulation is adapted for administration to a subject by nebulization with any known nebulizer. The formulation can be included in a kit. The formulation is administered as an aqueous solution, however, it can be stored as a dry powder, ready-to-use solution, or concentrated composition. The formulation is employed in an improved nebulization system for administering corticosteroid by inhalation. SAE-CD present in the formulation significantly enhances the chemical stability of budesonide. A method of administering the formulation by inhalation is provided. The formulation can also be administered by conventional nasal delivery apparatus.

The present invention provides novel processes and methodologies to minimize the bitter or otherwise unpleasant taste, to minimize the tendency to stimulate the cough reflex, or to minimize oropharyngeal deposition of medically-active compounds administered by the pulmonary/inhalation route and to deliver hydroxychloroquine (HCQ) either singularly or in combination with an antimalarial and aminoquinolone by the pulmonary/inhalation route in a sustained release or other formulation that minimizes the bitter or otherwise unpleasant taste of HCQ or any potential to stimulate the cough reflex, and to deliver a dopaminergic compound or its prodrug, including ABT-431 by the pulmonary/inhalation route in a sustained release or other formulation that minimizes the unpleasant taste of the drug or any potential to stimulate the cough reflex, and to deliver a lantibiotic, including duramycin by the pulmonary/inhalation route in a sustained release or other formulation that minimizes the unpleasant taste of the drug or any potential to stimulate throat irritation.

The invention relates to a compound inhalation preparation containing cephalosporin antibiotic and glucocorticoid and applications thereof. The cephalosporin antibiotic is made into an inhalation dosage form, so that the preparation can treat pulmonary bacterial infection with less dosage form and has a certain curative effect on asthma and chronic obstructive pneumonia at the same time.

Respirable inhalable particles comprising active agent(s) and excipients in at least a partially crystalline form and their uses thereof.

The invention provides a pharmaceutical composition for treating viral infection of respiratory system. The pharmaceutical composition contains chloroquine and a sputum-removing drug. The sputum-removing drug is selected from at least one of acetylcysteine, ambroxol or ammonium chloride. The invention provides a preparation method of the pharmaceutical composition for preventing and treating diseases caused by virus infection of a human respiratory system. The medicine composition of the chloroquine and sputum-removing drug is prepared into a spray, an aerosol or an inhalation preparation forpreventing and treating the diseases caused by the virus infection of the human respiratory system.

The invention belongs to the field of pharmaceutical preparations, and particularly relates to novel application of a houttuynia cordata and honeysuckle injection used for preparing a rectal administration preparation and an atomizing inhalation preparation. The houttuynia cordata and honeysuckle injection comprises the following raw materials: 3500-4500 parts of houttuynia cordata, and 1500-2500 parts of honeysuckle. The rectal administration preparation and the atomizing inhalation preparation have the characteristics that the rectal administration preparation and the atomizing inhalation preparation are quick in absorption, avoid first pass effect, are convenient to operate, have no pain and trauma, are easy to be accepted particularly by child patients, directly act on pathological changes tissue towards part diseases, are quick in effect, and improve bioavailability of the medicine, and has outstanding curative effect for infectious diseases.

The invention relates to the components and applications of a compound inhalation preparation containing an antifungal drug. When a trace amount of an antifungal drug is compounded with a drug for treating asthma and chronic obstructive pneumonia, a good curative effect will be generated; and the curative effect is more prominent, when the antifungal drug is compounded with glucocorticoid and an anti-cholinergic agent.

The invention discloses a preparation method of a guinea pig airway allergic asthma model. The preparation method comprises the steps as follows: (1) injecting an OVA (ovalbumin) normal saline solution into a guinea pig abdominal cavity once every other day, and injecting the solution two to four times totally to enable a guinea pig to be allergic; (2) on 12th-15th days after the last sensitization in Step (1), enabling the guinea pig to inhale the atomized OVA normal saline solution through the mouth and the nose so as to arouse airway allergic asthma. Compared with existing methods, the preparation method has the advantages that the aerosol inhalation delivery is simulated, an inhalation preparation for nasal delivery is simulated, the target organ is sole, the pertinence is high, and common guinea pig intravenous injection allergy arousing tests cannot predict whether the allergy is aroused due to inhalation of a drug through the respiratory tract or not. Experiments prove that the preparation method is good in allergic effect, the OVA normal saline solution which is only inhaled and atomized through the mouth and the nose serves as a way to arouse the allergy, and the guinea pig airway allergic asthma model is successfully established.

The invention discloses application of chlorogenic acid to preparing medicine for treating allergic rhinitis. The chlorogenic acid can be used for preparing compositions in diversified forms. The compositions include oral, injection and lung inhalation preparations and particularly include injection, oral liquid, tablets, capsules, granules, aerosol, powder aerosol and spray.

The invention belongs to the technical field of medicines, and discloses a lopinavir inhalation aerosol and a preparation method thereof. The lopinavir inhalation aerosol is composed of lopinavir serving as an active ingredient, a propellant, a cosolvent, a surfactant and the like according to a certain ratio . The aerosol inhalant is administrated through the oral cavity and directly acts on thelung to achieve targeted administration. The inhalation preparation disclosed by the invention can target a focus, is accurate in dosage, takes effect rapidly, can quickly improve the pulmonary infection condition, is beneficial to improve the adaptability of an infected person, and avoids gastrointestinal tract absorption so as to reduce side effects on the gastrointestinal tracts.

The invention relates to a compound inhalation preparation containing penicillin antibiotic and glucocorticoid and applications thereof. The preparation is capable of treating pulmonary bacterial infection with less dosage and has a certain curative effect on asthma and chronic obstructive pneumonia. The preparation is made into an dry powder inhalation dosage form, after a long period of preservation, the content of allergic matters namely penicilloic acid and penicillenic acid is not increased, so that the happening rate of allergy is largely reduced, when the preparation is used to treat asthma caused by non-microbial infection and chronic obstructive pneumonia.

Kits enabling an end user to efficiently compound inhalable formulations containing medicinal compounds, for use in in aerosol device (e-cigarette; personal vaporizer). Kits include a reusable storage device, a filling station, at least one predetermined amount aerosol precursor in a container and at least one empty cartomizer (cartridge) for use in an aerosol delivery device. Optionally, kits may also include a predetermined amount of extract containing a known amount of medicinal compound, enabling the production of an amount an inhalable formulation. Optionally, kits may contain amounts of inputs that enable the refilling/reuse of cartridges.

The invention relates to a novel inhalation preparation, in particular to a preparation suitable for inhalation drug administration of children ranging from 0 to 12 years. After medicine difficult to be dissolved in water and auxiliary materials are mixed, a wet grinding method is adopted for smashing, mixed suspension liquid containing particles with the particle size appropriate is obtained, the particle size is 0.1-7 microns, and preferentially, the particle size is 0.1-5 microns; and further, the preferential particle size is 0.1-3 microns. Solid powder is obtained through a freeze-drying method. Sealing is performed for obtaining the novel inhalation; and before use, the novel inhalation preparation is mixed with liquid suitable for atomization, re-dispersion is performed, and the mixed suspension liquid capable of being used for atomizing inhalation of children is obtained. The preparation is stored and transported in the form of the solid powder, the problem that when a mixed suspension liquid form is adopted, the physical stability and the chemical stability are poor is avoided, the medicine particle size hardly changes, impurity increase is little, and the content hardly changes. Compared with inhalation powder aerosol, the novel inhalation preparation is especially suitable for atomizing medicine administration of children, medicine smaller in particle size can be adopted, and even though under the situations that breathing of an infant is slight and the effective portion deposition rate is low, an ideal medicine effect can also be achieved.

The invention discloses an inhalation preparation containing calcitriol and budesonide and a preparation method thereof. The inhalation preparation containing calcitriol and budesonide comprises calcitriol and budesonide as active components and one or more pharmaceutic adjuvants suitable for inhaled drugs, wherein, the weight ratio of calcitriol to budesonide is 100-800:1. The inhalation preparation containing calcitriol and budesonide can be used for treating bronchial diseases in humans or mammals.

The invention relates to a device for measuring dissolution of an inhalation preparation. The device comprises a DUSA pipe, a dissolution medium pump and a dissolution medium container, wherein a flowmeter connecting head and a vacuum pump connecting head are respectively mounted at both ends of the DUSA pipe; the flowmeter connecting head is connected with the dissolution medium container througha first pipeline; the dissolution medium container is connected with one end of the dissolution medium pump through a second pipeline; and the vacuum pump connecting head is connected with the otherend of the dissolution medium pump through a third pipeline. The invention further relates to a method for measuring the dissolution of the inhalation preparation by adopting the above device. The dissolution device of the inhalation preparation makes up the vacancy of the existing dissolution device, the dissolution method is simple to operate, simulates the lung dissolution environment, is convenient to sample, adopts closed circulation dissolution in the whole dissolution process, is simple to apply and convenient to operate, and less in use of the dissolution medium in the whole dissolution process, and can select multiple operation parameters according to actual needs, so that the feasibility of a dissolution test of the inhalation preparation and the reliability of a dissolution result are guaranteed.

The invention belongs to the technical field of medicine, and discloses a chloroquine phosphate inhalation aerosol and a preparation method thereof. The chloroquine phosphate inhalation aerosol is composed of active ingredient chloroquine phosphate and a certain proportion of a propellant, a flavoring agent, a pH regulator and water for injection. The aerosol inhaler is administered through mouthsand directly acts on lungs to realize targeted drug delivery. The inhalation preparation provided by the invention can target lesion, has an accurate dosage and a fast effect, can quickly improve theinfection conditions of the lungs, facilitates improving the adaptability of infected people, and avoids absorption through gastrointestinal tracts to reduce gastrointestinal side effects.

The invention discloses application of an earthworm injection in atomization and rectal administration and a preparation method, a glabrous sarcandra herb injection, an ilex pubescens injection and anosmotic pressure regulator with the mass fraction of 0.2-0.3% are added into the earthworm injection, a pH regulator is used for adjusting the pH value to 6.3-6.8, an obtained solution is prepared into an atomized inhalation preparation by ultrasonic wave or a compression type atomization machine, and the atomized inhalation preparation is directly sucked into the respiratory system in an atomized form or covers the respiratory system in a local spraying manner; and a rectal absorption promoter with the mass fraction of 0.2-0.3% is added into the earthworm injection, the pH regulator is usedfor adjusting the pH value to 6.3-6.8, an obtained solution is prepared into a rectal administration preparation, or the obtained solution is put into a dropper to prepare a rectal drop irrigation preparation, and enters the blood circulation through rectal veins. The earthworm injection conforms to the physical and chemical property requirements of the respiratory system and the environment in the intestinal tract, and has no irritation to the respiratory tract and the intestinal tract, and the operation is simple; by virtue of different preparations, the earthworm injection can be used for clinically treating various diseases.

The invention provides a new medical application of a compound inhalation preparation of tiotropium bromide and formoterol, namely application to preparation of a medicament for treating lung cancer with chronic obstructive pulmonary disease. The compound inhalation preparation is prepared from tiotropium bromide, formoterol and pharmaceutic adjuvants, wherein the ratio of tiotropium bromide to formoterol is 2.5:1, 2.8:1 or 3:1. Studies show that tiotropium significantly inhibits the growth of lung cancer cells, inhibits the growth of lung cancer transplantable tumors, and produces a strongerbronchodilation effect. Formoterol has no effect on the growth of lung cancer cells and lung cancer transplantable tumors, but can significantly enhance the anti-lung cancer effect and bronchodilationeffect of tiotropium bromide. The compound preparation is administered by airway inhalation, so that the drug concentration of the target organ lung is greatly higher than that of system drug administration, the blood drug concentration and the distribution in other organs are greatly reduced, and the systemic adverse reaction is reduced. The compound inhalation preparation can be applied to treatment of lung cancer with chronic obstructive pulmonary disease.

The invention relates to the field of nano-drug inhalation preparations, in particular to preparation of naringin nano-inhalation powder inhalation taking polylysine PL as a carrier and research on the treatment effect of the naringin nano-inhalation powder inhalation on cough after infection. The preparation method comprises the following steps: firstly, preparing a naringin nano suspension by adopting a medium grinding method based on a Top-down principle, and then further drying and curing by adopting a spray drying method to obtain the naringin nano inhalation powder aerosol. The naringin nano inhalation powder inhalation disclosed by the invention is simple in preparation process, high in drug loading capacity and good in in-vivo release effect; in-vivo pharmacodynamic experiment results show that the prepared naringin nano inhalation dry powder can significantly improve the cough relieving, anti-inflammatory and anti-oxidation curative effects of the medicine, and the naringin nano inhalation dry powder enables the medicine and a carrier to be absolutely safe due to the fact that no organic reagent is added in the whole preparation process, and has great market application and popularization prospects.